I t takes a strong stomach to invest in biotech. Patients die in clinical trials. The smart money decides the sector is overpriced.
Politicians threaten to curb intellectual property rights.
But leading a biotech company is even tougher on the digestive tract than investing. Biotech CEOs must tough it out, making sure research and development doesn't falter, raising money and sustaining company morale. They get used to being the goat, when yesterday they were the hero. Nanogen Inc. These companies spent years overlooked by many investors and analysts but have recently emerged as industry stars. The leadership principles of their executives apply to any company in the investment doghouse.